{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:07:20Z","timestamp":1789729640040,"version":"4.0.1"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein, is overexpressed on the membranes of prostate cancer cells. Lutetium-177 (\n                    <jats:sup>177<\/jats:sup>\n                    Lu)- labelled PSMA-targeted radioligand therapy (PRLT) is employed in treating metastatic castration-resistant prostate cancer (mCRPC) that no longer responds to conventional therapies. However, some patients develop resistance or exhibit limited responsiveness, resulting in disease progression. Terbium-161 (\n                    <jats:sup>161<\/jats:sup>\n                    Tb) shares physical properties with\n                    <jats:sup>177<\/jats:sup>\n                    Lu, as both isotopes emit \u03b2\n                    <jats:sup>-<\/jats:sup>\n                    particles. Notably,\n                    <jats:sup>161<\/jats:sup>\n                    Tb also emits internal conversion and Auger electrons, offering potential advantages in the effective targeting of small lesions. This dual-emission mechanism enables the treatment of lesions of varying sizes, generating growing interest in\n                    <jats:sup>161<\/jats:sup>\n                    Tb-labelled radioligand therapy for prostate cancer. This review summarizes current evidence on\n                    <jats:sup>161<\/jats:sup>\n                    Tb-PSMA, including its mechanism of action, radiolabeling and quality-control procedures, dosimetry, preclinical results, and clinical outcomes, highlighting its therapeutic promise. Future investigations should further validate the safety and efficacy of\n                    <jats:sup>161<\/jats:sup>\n                    Tb-PSMA radioligand therapy, while enhancing its accessibility and clinical translation.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2025.1743628","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:39:41Z","timestamp":1768372781000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["161Tb-PSMA radioligand therapy in prostate cancer: current evidence and future perspectives"],"prefix":"10.3389","volume":"15","author":[{"given":"Liming","family":"Xiao","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Mianyang Central Hospital","place":["Mianyang, China"]},{"name":"National Health Commission (NHC) Key Laboratory of Nuclear Technology Medical Transformation (Mianyang Central Hospital)","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Mianyang Central Hospital","place":["Mianyang, China"]},{"name":"National Health Commission (NHC) Key Laboratory of Nuclear Technology Medical Transformation (Mianyang Central Hospital)","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Mianyang Central Hospital","place":["Mianyang, China"]},{"name":"National Health Commission (NHC) Key Laboratory of Nuclear Technology Medical Transformation (Mianyang Central Hospital)","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fucen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Mianyang Central Hospital","place":["Mianyang, China"]},{"name":"National Health Commission (NHC) Key Laboratory of Nuclear Technology Medical Transformation (Mianyang Central Hospital)","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bosen","family":"Hu","sequence":"additional","affiliation":[{"name":"National Defense Technology College of Southwest University of Science and Technology","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Institute of Nuclear Physics and Chemistry, Chinese Academy of Engineering Physics","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Yang","sequence":"additional","affiliation":[{"name":"Institute of Nuclear Physics and Chemistry, Chinese Academy of Engineering Physics","place":["Mianyang, China"]},{"name":"Targeted Radiopharmaceuticals Creation Key Laboratory of Sichuan Province","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengguo","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Mianyang Central Hospital","place":["Mianyang, China"]},{"name":"National Health Commission (NHC) Key Laboratory of Nuclear Technology Medical Transformation (Mianyang Central Hospital)","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Ctr"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.11.013","article-title":"Recent patterns and trends in global prostate cancer incidence and mortality: an update","volume":"87","author":"Schafer","year":"2025","journal-title":"Eur Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: Esmo Clinical Practice Guidelines for diagnosis, treatment and follow-Up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"Eau-Eanm-Estro-Esur-Isup-Siog guidelines on prostate cancer. Part II\u20142024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2024.0139","article-title":"Luteinizing hormone-releasing hormone receptor agonists and antagonists in prostate cancer: effects on long-term survival and combined therapy with next-generation hormonal agents","volume":"21","author":"Zhao","year":"2024","journal-title":"Cancer Biol Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70020","article-title":"The contemporary management of prostate cancer","volume":"75","author":"Chakrabarti","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30040323","article-title":"Metastatic castration-resistant prostate cancer, immune checkpoint inhibitors, and beyond","volume":"30","author":"Lanka","year":"2023","journal-title":"Curr Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)01653-2","article-title":"177lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a Phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06316-y","article-title":"Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics","volume":"50","author":"M\u00fcller","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153638","article-title":"The role of PSMA PET\/CT in the primary diagnosis and follow-up of prostate cancer\u2014a practical clinical review","volume":"14","author":"Lisney","year":"2022","journal-title":"Cancers"},{"key":"B13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1053\/j.semnuclmed.2023.07.001","article-title":"PSMA PET\/CT for primary staging of prostate cancer - an updated overview","volume":"54","author":"Jochumsen","year":"2024","journal-title":"Semin Nucl Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-21-4531","article-title":"Prostate-specific membrane antigen expression and response to DNA damaging agents in prostate cancer","volume":"28","author":"Sheehan","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231182293","article-title":"The current status of prostate cancer treatment and PSMA theranostics","volume":"15","author":"Uemura","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00259-019-04529-8","article-title":"Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients","volume":"47","author":"Vaz","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268340","article-title":"Exploring the flare phenomenon in patients with castration-resistant prostate cancer: enzalutamide-induced PSMA upregulation observed on PSMA PET","volume":"66","author":"van der Gaag","year":"2025","journal-title":"J Nucl Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00135-9","article-title":"177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00009-9","article-title":"Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000003925","article-title":"225Ac-prostate-specific membrane antigen therapy for castration-resistant prostate cancer","volume":"46","author":"Sanli","year":"2021","journal-title":"Clin Nucl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04345-0","article-title":"Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer","volume":"46","author":"M\u00fcller","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.796657","article-title":"Efficacy and safety of 225Ac-PSMA-617-targeted alpha therapy in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis","volume":"12","author":"Ma","year":"2022","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.7150\/thno.92775","article-title":"Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside","volume":"14","author":"Van Laere","year":"2024","journal-title":"Theranostics"},{"key":"B26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40658-023-00589-w","article-title":"Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection","volume":"10","author":"Verburg","year":"2023","journal-title":"EJNMMI Phys"},{"key":"B27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40658-022-00495-7","article-title":"Active bone marrow S-Values for the low-energy electron emitter terbium-161 compared to S-Values for lutetium-177 and yttrium-90","volume":"9","author":"Hemmingsson","year":"2022","journal-title":"EJNMMI Phys"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.170423","article-title":"Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: implications for radiopharmaceutical therapy","volume":"57","author":"Hindi\u00e9","year":"2016","journal-title":"J Nucl Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40658-020-00301-2","article-title":"Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases","volume":"7","author":"Alcocer-\u00c1vila","year":"2020","journal-title":"EJNMMI Phys"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265509","article-title":"Membrane and nuclear absorbed doses from 177Lu and 161Tb in tumor clusters: effect of cellular heterogeneity and potential benefit of dual targeting\u2014a Monte Carlo study","volume":"64","author":"Larouze","year":"2023","journal-title":"J Nucl Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2023.110927","article-title":"Can we reach suitable 161Tb purity for medical applications using the 160Gd(d,n) reaction","volume":"200","author":"Nigron","year":"2023","journal-title":"Appl Radiat Isot"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2023.110840","article-title":"Photonuclear production of medical radioisotopes 161Tb and 155Tb","volume":"198","author":"Fedotova","year":"2023","journal-title":"Appl Radiat Isot"},{"key":"B33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s41181-019-0063-6","article-title":"Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy","volume":"4","author":"Gracheva","year":"2019","journal-title":"EJNMMI Radiopharm Ch"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2024.465439","article-title":"Production and radiochemical separation of Tb-161 as a feasible beta therapeutic radioisotope from reactor irradiated Gd Target","volume":"1737","author":"Gizawy","year":"2024","journal-title":"J Chromatogr A"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2024.111530","article-title":"The production and separation of 161Tb with high specific activity at the University of Utah","volume":"214","author":"Holiski","year":"2024","journal-title":"Appl Radiat Isot"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25040966","article-title":"A step-by-step guide for the novel radiometal production for medical applications: case studies with 68Ga, 44Sc, 177Lu and 161Tb","volume":"25","author":"Talip","year":"2020","journal-title":"Molecules"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s10967-024-09809-8","article-title":"The radiolabeling of [161Tb]Tb-PSMA-617 by a novel radiolabeling method and preclinical evaluation by in vitro\/in vivo methods","volume":"333","author":"Uygur","year":"2024","journal-title":"J Radioanal Nucl Ch"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s10967-025-10352-3","article-title":"Terbium-161 PSMA therapy in mCRPC patient based on an optimized radiolabeling protocol","volume":"334","author":"Sezgin","year":"2025","journal-title":"J Radioanal Nucl Ch"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092011","article-title":"Dosimetric analysis of the short-ranged particle emitter 161Tb for radionuclide therapy of metastatic prostate cancer","volume":"13","author":"Bernhardt","year":"2021","journal-title":"Cancers"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/bf01254561","article-title":"Evaluation in vitro and in rats of 161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy","volume":"22","author":"de Jong","year":"1995","journal-title":"Eur J Nucl Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05564-0","article-title":"Combination of terbium-161 with somatostatin receptor antagonists\u2014a potential paradigm shift for the treatment of neuroendocrine neoplasms","volume":"49","author":"Borgna","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266233","article-title":"Preclinical evaluation of gastrin-releasing peptide receptor antagonists labeled with 161Tb and 177Lu: A comparative study","volume":"65","author":"Holzleitner","year":"2024","journal-title":"J Nucl Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2798-3","article-title":"Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model","volume":"41","author":"Gr\u00fcnberg","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265524","article-title":"Albumin-binding and conventional PSMA ligands in combination with 161Tb: biodistribution, dosimetry, and preclinical therapy","volume":"64","author":"Tschan","year":"2023","journal-title":"J Nucl Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000004589","article-title":"New horizons in radioligand therapy","volume":"48","author":"Rosar","year":"2023","journal-title":"Clin Nucl Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265291","article-title":"161Tb-PSMA radioligand therapy: first-in-humans SPECT\/CT imaging","volume":"64","author":"Al-Ibraheem","year":"2023","journal-title":"J Nucl Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.7150\/thno.92273","article-title":"161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]Lu-PSMA-617","volume":"14","author":"Schaefer-Schuler","year":"2024","journal-title":"Theranostics"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16111974","article-title":"From despair to hope: first Arabic experience of 177Lu-PSMA and 161Tb-PSMA therapy for metastatic castration-resistant prostate cancer","volume":"16","author":"Al-Ibraheem","year":"2024","journal-title":"Cancers"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s13139-024-00871-4","article-title":"Dual radionuclide therapy: the synergistic effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in advanced prostate cancer post [177Lu]Lu-PSMA failure","volume":"58","author":"Abdlkadir","year":"2024","journal-title":"Nucl Med Molec Imag"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-07009-w","article-title":"First-in-human administration of [161Tb]Tb-Sibudab and comparative dosimetry with standard [177Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study","volume":"52","author":"Chirindel","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00332-8","article-title":"First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta\u2013Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1\/2 study","volume":"26","author":"Buteau","year":"2025","journal-title":"Lancet Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270952","article-title":"Initial multicenter experience with [161Tb]Tb-PSMA in [177Lu]Lu-PSMA\u2013refractory metastatic castration-resistant prostate cancer: preliminary results","volume":"66","author":"Kucuk","year":"2025","journal-title":"J Nucl Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267650","article-title":"Clinical trial protocol for VIOLET: A single-center, phase I\/II trial evaluation of radioligand treatment in patients with metastatic castration-resistant prostate cancer with [161Tb]Tb-PSMA-I&T","volume":"65","author":"Buteau","year":"2024","journal-title":"J Nucl Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2021.03.004","article-title":"A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177\u2013labeled prostate-specific membrane antigen\u2013targeted radioligand therapy in metastatic castration-resistant prostate cancer","volume":"80","author":"Sadaghiani","year":"2021","journal-title":"Eur Urol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.835956","article-title":"177Lu-PSMA-I&T radioligand therapy for treating metastatic castration-resistant prostate cancer: A single-centre study in East Asians","volume":"12","author":"Bu","year":"2022","journal-title":"Front Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262713","article-title":"Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry","volume":"63","author":"Schuchardt","year":"2022","journal-title":"J Nucl Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231187202","article-title":"Novel radionuclide therapy combinations in prostate cancer","volume":"15","author":"Inderjeeth","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267611","article-title":"Is 161Tb really happening","volume":"65","author":"Kong","year":"2024","journal-title":"J Nucl Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1743628\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:39:42Z","timestamp":1768372782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1743628\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":58,"alternative-id":["10.3389\/fonc.2025.1743628"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1743628","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"article-number":"1743628"}}